
What do the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) say about KISQALI in HR+/HER2- early (stage II/III at high risk of recurrence) and metastatic breast cancer?

National Comprehensive Cancer Network® (NCCN®) differentiates ribociclib (KISQALI®) as the first and only Category 1 Preferred treatment option when used in combination with an AI for appropriate patients with HR+/HER2- mBC in 1L and for appropriate patients with HR+/HER2- eBC, including those with high-risk node-negative disease.1
In HR+/HER2- eBC, high-risk node-negative disease is defined as either tumor size >5 cm, or if tumor size 2-5 cm, either grade 2 (with high genomic risk or Ki-67 ≥20%), or grade 3.1
There is controversy on the choice of CDK4/6 inhibitor as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.1
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.1
Category 1: Based upon high-level evidence (≥1 randomized phase III trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.1
1L, first line; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; eBC, early breast cancer; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive; mBC, metastatic breast cancer.
Take a closer look at what the NCCN Guidelines® for Breast Cancer say about KISQALI: Download the clinical flashcard
MORE oncologists’ top choice

KISQALI is the most prescribed CDK4/6 inhibitor across both HR+/HER2- eBC & mBC
See what KISQALI could mean for the patients in your practice
Get additional information and resources on the NCCN Guidelines for ribociclib (KISQALI) and KISQALI access
